Management of hereditary angioedema (HAE) - Analysis of 39 patients;Leczenie wrodzonego obrzȩku naczynioruchowego - Opis 39 pacjentów

Alergia Astma Immunologia

Volumn 12, Issue 4, 2007, Pages 200-209

  Nowicka, Ewa ^a,b   Najberg, Ewa ^a   Gregorek, Hanna ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b Poradnia Alergologiczna IP CZD   (Poland)

Author keywords

HAE; Prophylaxis; Treatment of acute oedemas

Indexed keywords

AMINOCAPROIC ACID; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; DANAZOL; TRANEXAMIC ACID;

ABDOMINAL DISEASE; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG MEGADOSE; EDEMA; FAMILY HISTORY; FEMALE; HEALTH EDUCATION; HUMAN; LARYNX EDEMA; MALE; MEDICAL INFORMATICS; MENSTRUATION DISORDER; QUESTIONNAIRE; SCHOOL CHILD;

EID: 40949103170     PISSN: 14273101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Gomples MM, Lock RJ, Abinum M, Bethune CA, Davis G i wsp. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005; 139: 379-394.
2. Johnson AM, Alper CA, Rosen FS, Craig JM. C1-inhibitor: evidence for decreased hepatic synthesis in hereditary angioedema. Science. 1971; 173: 553-554.
3. Zuraw BL, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol. 2000; 105: 541-546.
4. Pappalardo E, Cicardi M, Duponchel C i wsp. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunology. 2000; 106: 1147-1154.
5. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review of clinicians. Arch Int Med. 2001; 161: 2417-2429.
6. Madaliński K. Dziedziczny obrzȩk naczynioruchowy. Lekarz rodzinny. 2001; 9: 26-29.
7. DavisAE. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003; 29: 195-203.
8. Nussgerger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykininin angio-oedema, Lancet. 1998; 351: 1693-1697.
9. Ciebiada A, Kowalski M. Obrzȩk naczynioruchowy spowodowany niedoborem inhibitora dla składnika C1 dopełniacza. Alergia Astma Immunol. 2000; 5: 43-49.
10. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003; 29: 239-245.
11. Gomples MM, Lock RJ, Morgan JE, Osborne J i wsp. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol. 2002; 55: 145-147.
12. Jaworska H, Gregorek H, Madaliński K. Obrzȩk naczynioruchowy zależny od defektu syntezy C1-inhibitora. Przegla̧d Lekarski. 2000; 57: 483-488.
13. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Int Med. 976; 84: 586-593.
14. Nowicka E, Najberg E, Madaliński K, Gregorek H. Dziedziczny obrzȩk naczynioruchowy-obraz kliniczny (rejestr warszawski). Alergia Astma Immunol. 2005; 10: 27-31.
15. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema, Transfus Apher Sci. 2003; 29: 221-227.
16. Obtułowicz K. Obrzȩk naczynioruchowy-trudny problem kliniczny. Alergia Astma Immunol. 2006; 11(supl. 1): 166-171.
17. Madaliński K, Obtułowicz K. Management of complement C1 inhibitor deficiency. Alergia Astma Immunol. 2000; 5: 235-236
18. Bork K, Hardt J, Schicketanz KH i wsp. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 inhibitor deficiency. Arch Int Med. 2003; 163: 1229-1235.
19. Nielsen EW, Kjernlie DF, Aaseth J. A fatal case of hereditary angioedema. Tidsskr-Nor-Laegeforen. 1995; 115: 43-44.
20. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci. 2003; 29: 235-238.
21. Ciebiada A, Kubicka M, Kowalski M. Wrodzony obrzȩk naczynioruchowy - opis dwóch rodzin z ocena̧ leczenia danazolem. Alergia Astma Immunol. 1999; 4: 30-36.
22. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacts of abdominal pain induced by oral contraceptives and hormone replacement therapy. Am J Med. 2003; 114: 294-298.
23. Agostoni A, Cicardi M. Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency. Am J Med. 1991; 90: 278-279.
24. Katelaris C. Obrzȩk naczynioruchowy górnych dróg oddechowych, Przegla̧dAlergologiczny. 2005; 3: 13-17.
25. Agostoni A, Cicardi M, Martignoni GC i wsp. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol. 1980; 65: 75-79.
26. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med. 1963; 35: 37-44.
27. Bowen T, Hebert J, Ritchie B i wsp. Management of hereditary angioedema: a Canadian approach, Transfus Apher Sci. 2003; 29: 205-214.
28. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angioedema. Lancet. 1999; 353: 1066-1067.
29. Farkas H, Harmat G, Fust G, Varga L, Visy B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002; 13: 153-161.
30. Farkas H, Harmat G, Gyeney L, Fust G, Varga L. Danazol therapy for hereditary angio-oedema in children. Lancet. 1999; 352: 1031-1032.
31. Farkas H, Gyeney L, Gidofalvy E i wsp. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillo-facial and dental procedures. J Oral Maxill Surg. 1998; 57: 404-408.
32. Farkas H, Harmat G, Kaposi NP, Karadi I i wsp. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacts of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol. 2001; 13: 1225-1230.
33. Mohr M, Pollok-Kopp B, Gotze O, Burchardi H. The use of a C1-inhibitor concentrate for short-term preoperative prophylaxis in two patients with HAE. Anaesthetist. 1996; 45: 626-630.
34. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996; 334: 1630-1634.
35. Bork K, Bamstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Int Med. 2001; 161: 714-718.
36. Visentin DE, Yang W, Karsh J. C1-esterase inhibitor transfusions in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 1998; 80: 457-461.
37. Zingale LC, Pappalardo E, Zanichelli A. i wsp. C1 inhibitor concentrate: efficacy and adverse reactions. Int Immunopharmacol. 2002; 318: 1385 (abs.).
38. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-215.
39. Bas M, Adams V, Suvorova T. i wsp. Nonallergic angioedema: role of bradykinin. Allergy. 2007; 62: 842-856.
40. van Doorn MB, Burggraaf J, van Dam T i wsp. A faze I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005; 116: 876-883.
41. Bas M, Bier H, Greve J i wsp. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B-2-receptor antagonist incatibant. Allergy. 2006; 61: 1490-1492.